Navigation Links
Hepatitis Rates Soar Among IV Drug Users, Study Finds
Date:7/27/2011

WEDNESDAY, July 27 (HealthDay News) -- About 10 million injection drug users worldwide have hepatitis C, and 1.3 million have hepatitis B, a new study reports.

Hepatitis can lead to cirrhosis, liver failure and liver cancer.

Researchers analyzed international data and found that rates of hepatitis C infection among injection drug users (IDUs) were 60 to 80 percent in 25 countries and greater than 80 percent in 12 other countries.

These countries included Spain (80 percent), Norway (76 percent), Germany (75 percent), France (74 percent), United States (73 percent), China (67 percent), Canada (64 percent), Italy (81 percent), Portugal (83 percent), Pakistan (84 percent), the Netherlands (86 percent), Thailand (90 percent) and Mexico (97 percent).

Lower rates were seen in New Zealand (52 percent), Australia (55 percent) and the United Kingdom (50 percent), the researchers noted.

The countries believed to have the largest number of IDUs infected with hepatitis C virus (HCV) are China (1.6 million), the United States (1.5 million) and Russia (1.3 million), the investigators found.

Rates of hepatitis B infection were 5 to 10 percent in 21 countries and more than 10 percent in 10 countries. The highest rates were in Vietnam (20 percent), Estonia (19 percent), Saudi Arabia (18 percent) and Taiwan (17 percent). The United Kingdom had the highest rate in Western Europe at 9 percent. The rate in the United States was 12 percent.

The study, released to coincide with World Hepatitis Day, is published online July 28 in The Lancet.

"The public-health response to blood-borne virus transmission in IDUs has mainly centered on HIV. Maintenance and strengthening of the response to HIV in IDUs remains crucial, but the significance of viral hepatitis needs to receive greater attention than it does at present," Paul Nelson, from the National Drug and Alcohol Research Centre at the University of New South Wales in Sydney, and colleagues wrote.

"Efforts to prevent, treat, and reduce harms related to liver disease in IDUs are essential -- especially in situations in which HIV has successfully been prevented or managed -- because the large numbers of IDUs infected with HCV and significant morbidity resulting from this infection mean that the health and economic costs of HCV transmitted by injected drug use might be as high as (or higher than) those of HIV," the authors added.

"Nonetheless, HCV treatment is underused. Part of the reason for this neglect is the high cost, which will remain a substantial barrier to increasing of treatment coverage in low-resource settings until costs are reduced," the researchers concluded.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about viral hepatitis.

-- Robert Preidt

SOURCE: The Lancet, news release, July 27, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China
2. Hepatitis B vaccination for health care students lags behind recommendations
3. Hepatitis C is transmitted by unprotected sex between HIV-infected men
4. P7 protein resistance mutations identified; represent drug targets for hepatitis C virus
5. Stepped-up vaccine series for hepatitis B is effective during pregnancy
6. New Drug Effectively Treats Hepatitis C
7. NEJM study: New drug represents breakthrough in treatment of hepatitis C
8. Noninvasive liver tests may predict hepatitis C patient survival
9. Analysis finds mortality from all causes higher among hepatitis C-infected
10. Scientists create humanized mouse model for hepatitis C
11. Coffee drinking improves hepatitis C treatment response
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hepatitis Rates Soar Among IV Drug Users, Study Finds
(Date:8/22/2017)... ... 22, 2017 , ... “To Walk Away”: a captivating and romantic sequel ... Koontz. “To Walk Away” is the creation of published author, Larry R. Sherman, a ... manuscripts in chemistry and religion, as well as four novels. , Though the ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s spiritual ... published author, Julianne Hale, a consultant for the Intelligence Community. For more ... on the Near East region. Julianne has written hundreds of reports for ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... TopConsumerReviews.com recently ... to fight Fatigue . , As the stress of modern life continually makes ... the pace. Constant use of artificial stimulants can trap people in vicious high/low cycles ...
(Date:8/21/2017)... ... , ... PracticeMatch, a company that provides online resources , job ... practitioners like nurse practitioners and physician assistants , will conduct its ... year. The online career fairs will allow job seekers to connect with healthcare employers ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los ... plastic surgery fellows for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz ... completed residency in Plastic and Reconstructive Surgery. The candidate will have the ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... E.I. Medical Imaging (EIMI) has partnered with ... design the worlds first ultrasound system to be used underwater ... habitat. In preparation for a piece produced by Icon ... Dr. Guttridge approached EIMI with the idea of an underwater ... sharks underwater. EIMI ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 The ... treat rare nervous system diseases, has concluded a worldwide license ... the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing ... in a Phase 2 study conducted in Europe ... the United States ...
Breaking Medicine Technology: